🔎 Trials Near Me

Hem › Akut myeloid leukemi › North Carolina

Kliniska studier för Akut myeloid leukemi i North Carolina

43 studier för Akut myeloid leukemi söker deltagare vid platser i North Carolina.

Städer i North Carolina

Officiell studietext (engelska)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • AdventHealth Infusion Center Asheville, Asheville
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • AdventHealth Infusion Center Haywood, Clyde
  • och 6 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Wake Forest University Health Sciences, Winston-Salem
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Novant Health Presbyterian Medical Center, Charlotte
  • Duke University Medical Center, Durham
  • och 3 fler
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 28 sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Atrium Health, Charlotte
  • Novant Health Charlotte, Charlotte
  • Carolina Oncology Specialists, Charlotte
  • och 2 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Novant Health Presbyterian Medical Center, Charlotte
  • och 5 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • och 1 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • och 1 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • och 1 fler
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 22 sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • och 4 fler
RekryterarFas 3
6 Months – 21 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Duke University Medical Center, Durham
RekryterarFas 1/2
30 Days · Alla kön · Uppdaterad 16 sep. 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Novant Health Clinical Research, Charlotte
  • East Carolina University, Greenville
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 16 sep. 2026 · NCT06824168

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • University of North Carolina at Chapel Hill, Chapel Hill
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT06846606

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • UNC School of Medicine, Division of Hematology, Chapel Hill
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 3 sep. 2026 · NCT04588922

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • Novant Health Weisiger Cancer Institute, Charlotte
RekryterarObservationsstudie
Ålder 0 och äldre · Alla kön · Uppdaterad 2 sep. 2026 · NCT07154823

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

  • Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 sep. 2026 · NCT07471841

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 2 sep. 2026 · NCT06652438

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Wake Forest University Health Sciences, Winston-Salem
RekryterarFas 1
Ålder 18 till 75 · Alla kön · Uppdaterad 25 aug. 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • och 4 fler
RekryterarFas 1/2
Upp till ålder 22 · Alla kön · Uppdaterad 25 aug. 2026 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of North Carolina, Chapel Hill, Chapel Hill
  • Duke University Medical Center, Durham
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Atrium Health Levine Cancer Center, Charlotte
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • University of North Carolina at Chapel Hill, Chapel Hill
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT06656494

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

  • Levine Cancer Institute, Charlotte
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 24 juli 2026 · NCT06580106

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

  • Levine Cancer Insitute, Charlotte
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Rekryterar
Ålder 18 till 64 · Alla kön · Uppdaterad 23 juli 2026 · NCT06945042

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  • Research Site, Chapel Hill
  • Research Site, Durham
RekryterarFas 1/2
Ålder 16 och äldre · Alla kön · Uppdaterad 20 juli 2026 · NCT07155226

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 juli 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Levine Children's Hospital, Charlotte
  • Duke University Medical Center, Durham
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 6 juli 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

  • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
Rekryterar
Ålder 60 och äldre · Alla kön · Uppdaterad 6 juli 2026 · NCT06697600

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • och 4 fler
RekryterarObservationsstudie
Ålder 65 och äldre · Alla kön · Uppdaterad 29 juni 2026 · NCT01137825

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 23 juni 2026 · NCT05401097

A Study of Revumenib and Mezigdomide in People With Leukemia

  • University of North Carolina (Data Collection Only), Chapel Hill
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 22 juni 2026 · NCT07356154

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 14 maj 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of North Carolina, Chapel Hill
RekryterarFas 1
Ålder 13 och äldre · Alla kön · Uppdaterad 5 maj 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Duke University, Durham
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 apr. 2026 · NCT04256317

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

  • Wake Forest Baptist Health, Winston-Salem
RekryterarObservationsstudie
Ålder 18 till 120 · Alla kön · Uppdaterad 13 apr. 2026 · NCT01890486

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • UNC Hospital, Chapel Hill
  • Duke University, Durham
  • Atrium Wake Forest Baptist Medical Center, Winston-Salem
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 24 mars 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Duke Blood Cancer Center, Durham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 13 mars 2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  • Duke Cancer Center, Durham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 16 jan. 2026 · NCT05143996

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

  • Novant Health Cancer Institute, Charlotte
  • Novant Health Cancer Institute, Winston-Salem
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 dec. 2025 · NCT06680752

Novel Digital Application for Patients With Acute Leukemia

  • Duke University, Durham
Rekryterar
Ålder 18 till 120 · Alla kön · Uppdaterad 10 nov. 2025 · NCT06472128

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.